

The Medical Letter[®]

on Drugs and Therapeutics

Volume 63

January 25, 2021

ISSUE No.
1616

IN THIS ISSUE

FDA Authorizes Moderna COVID-19 Vaccinep 9

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769

The Medical Letter[®]

on Drugs and Therapeutics

Volume 63 (Issue 1616)

January 25, 2021

Take CME Exams

FDA Authorizes Moderna COVID-19 Vaccine

Revised: On March 3, 2021, the CDC changed the "contraindication" to use of a mRNA COVID-19 vaccine in patients with polysorbate allergy to a "precaution": <https://bit.ly/38i7CIH>. The last paragraph of the Adverse Effects section has been updated to reflect this. 4/5/21: The Storage and Administration section has been updated.

On December 18, 2020, the FDA issued an Emergency Use Authorization (EUA) for the Moderna mRNA-based vaccine for prevention of COVID-19 in persons ≥ 18 years old. The Pfizer-BioNTech mRNA-based vaccine received an FDA EUA for the same indication in persons ≥ 16 years old on December 11, 2020.¹

CLINICAL STUDY – Issuance of the EUA was based primarily on the results of an observer-blind trial in which 30,420 subjects ≥ 18 years old were randomized 1:1 to receive the Moderna vaccine or placebo at 0 and 4 weeks. Immunocompromised persons and those with a history of SARS-CoV-2 infection were excluded. There were 11 cases of COVID-19 among subjects who received the vaccine and 185 cases among those who received placebo; the vaccine efficacy rate was 94.1%. In adults ≥ 65 years old, the vaccine efficacy rate was 86.4%. Severe COVID-19 occurred in 0 subjects who received the vaccine and in 30 of those who received placebo.²

ADVERSE EFFECTS – Fatigue, chills, headache, muscle and joint pain, fever, nausea/vomiting, axillary swelling/tenderness, and injection-site pain, erythema and swelling were reported following administration of the vaccine. Adverse effects were more frequent and severe following the second dose.²

Cases of anaphylaxis and anaphylactoid reactions to the Moderna and Pfizer-BioNTech COVID-19 vaccines have been reported; a CDC analysis of adverse effects following administration of ~ 1.9 million first doses of the Pfizer-BioNTech vaccine found the rate of anaphylaxis to be 11.1 per million doses.³ Experts have theorized that polyethylene glycol (PEG), which is present in both vaccines, may be the cause of these reactions. Both vaccines are contraindicated for use in persons with a history of an immediate or severe allergic reaction to a previous dose of an mRNA vaccine or any of its components, including PEG; a

Table 1. Moderna COVID-19 Vaccine¹

Formulation	Frozen suspension in multi-dose vials
Dosage	100 mcg (0.5 mL) IM at 0 and 1 month
Efficacy	94.1% (86.4% in subjects ≥ 65 years old)
Severe Adverse Effects ²	Myalgia (10.1%), arthralgia (5.9%), headache (5.0%), injection-site pain (4.6%)
Storage	Frozen in original carton; refrigerated ≤ 30 days

1. FDA. Fact sheet for healthcare providers administering vaccine (vaccination providers). Emergency Use Authorization (EUA) of the Moderna COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). December 2020. Available at <https://bit.ly/3nosyIA>. Accessed January 7, 2021.
2. Incidence of severe adverse effects after the second dose.

history of allergy to polysorbate, which is structurally related to PEG, is a precaution to use of a mRNA COVID-19 vaccine. Appropriate medical treatment used to manage allergic reactions must be available for use following administration of an mRNA COVID-19 vaccine. Persons with any history of immediate allergic reaction to a vaccine or injectable therapy or any history of anaphylaxis should be observed for 30 minutes after vaccination; other persons should be observed for 15 minutes after vaccination.⁴

PREGNANCY AND LACTATION – Pregnant women with COVID-19 are at increased risk for morbidity and mortality. According to the FDA, data on the Moderna vaccine are insufficient to inform vaccine-associated risk in pregnancy. Data on the effects of the vaccine on the breastfed infant or on milk production are not available.⁵ The American College of Obstetricians and Gynecologists (ACOG) recommends that the vaccine not be withheld from pregnant or lactating women who are otherwise eligible for vaccination.⁶

STORAGE AND ADMINISTRATION – The Moderna vaccine is supplied in frozen vials that contain either 10-11 or 13-15 0.5-mL doses. Residual vaccine from multiple vials should not be combined to form a full dose. The vials should be stored in the original carton at -25°C to -15°C . They should not be kept on dry ice. The vials can be stored in a standard refrigerator for ≤ 30 days prior to first use; doses cannot be refrozen once thawed. Prior to administration, frozen vaccine should be thawed in a refrigerator at 2°C to 8°C for 2.5 hours (11-dose vials) or 3 hours (15-dose vials), or at room temperature (15° to 25°C) for 1 hour (11-dose vials)

or 1.5 hours (15-dose vials). If refrigerated, vials should stand at room temperature for 15 minutes before vaccine administration.

Unpunctured vials can be stored at 8–25°C for up to 24 hours. After the first dose has been withdrawn, the vial should be kept at 2–25°C and discarded after 12 hours. The vaccine should be swirled gently after thawing and before each withdrawal, but should not be diluted or shaken.⁵

IMMUNIZATION PRIORITY – The CDC Advisory Committee on Immunization Practices (ACIP) recommends that healthcare personnel and long-term care facility residents be immunized first. Frontline essential workers and adults ≥ 75 years old are in the second priority group.⁷

The CDC has required state and local jurisdictions to develop vaccination plans for various phases of supply availability. Vaccines will generally be allocated to states and other jurisdictions based on population. State executives and health departments will be responsible for interpreting ACIP guidance and determining where the vaccine should be shipped and who should receive it.⁸ ■

1. FDA authorizes Pfizer-BioNTech COVID-19 vaccine. *Med Lett Drugs Ther* 2021; 63:1.
2. LR Baden et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N Engl J Med* 2020 December 30 (epub).
3. CDC. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14–23, 2020. *MMWR Morb Mortal Wkly Rep* 2021 January 6 (epub).
4. CDC. Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States. January 6, 2021. Available at: <http://bit.ly/38i7CIH>. Accessed January 7, 2021.
5. FDA. Fact sheet for healthcare providers administering vaccine (vaccination providers). Emergency Use Authorization (EUA) of the Moderna COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). March 2021. Available at: <https://bit.ly/3nosylA>. Accessed April 5, 2021.
6. ACOG. Vaccinating pregnant and lactating patients against COVID-19. December 21, 2020. Available at: <http://bit.ly/2Kt7AnS>. Accessed January 7, 2021.
7. CDC Advisory Committee on Immunization Practices (ACIP). Phased allocation of COVID-19 vaccines. December 20, 2020. Available at: <https://bit.ly/38rMVJa>. Accessed January 7, 2021.
8. CDC. COVID-19 vaccination program interim playbook for jurisdiction operations – October 29, 2020. Version 2.0. Available at: <https://bit.ly/37Slp63>. Accessed January 7, 2021.

Online Table: Treatments Considered for COVID-19

Please check our website for the latest information on COVID-19, including our continuously updated table, Treatments Considered for COVID-19. Available at: www.medicalletter.org/drugs-for-covid-19.

PRESIDENT: Mark Abramowicz, M.D.; **VICE PRESIDENT AND EXECUTIVE EDITOR:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School
VICE PRESIDENT AND EDITOR IN CHIEF: Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhM, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Franco M. Muggia, M.D., New York University Medical Center; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli
EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:
 The Medical Letter, Inc.
 145 Huguenot St. Ste. 312
 New Rochelle, NY 10801-7537
www.medicalletter.org

Customer Service:
 Call: 800-211-2769 or 914-235-0500
 Fax: 914-632-1733
 E-mail: custserv@medicalletter.org

Permissions:
 To reproduce any portion of this issue,
 please e-mail your request to:
permissions@medicalletter.org

Subscriptions (US):
 1 year - \$159; 2 years - \$298;
 3 years - \$398. \$65 per year
 for students, interns, residents,
 and fellows in the US and Canada.
 Reprints - \$45 per issue or article

Site License Inquiries:
 E-mail: SubQuote@medicalletter.org
 Call: 800-211-2769
 Special rates available for bulk
 subscriptions.

Get Connected:  

Copyright 2021. ISSN 1523-2859

